BRPI0417493A - terapia com toxina botulìnica para distúrbios da pele - Google Patents

terapia com toxina botulìnica para distúrbios da pele

Info

Publication number
BRPI0417493A
BRPI0417493A BRPI0417493-3A BRPI0417493A BRPI0417493A BR PI0417493 A BRPI0417493 A BR PI0417493A BR PI0417493 A BRPI0417493 A BR PI0417493A BR PI0417493 A BRPI0417493 A BR PI0417493A
Authority
BR
Brazil
Prior art keywords
skin disorders
botulically
toxin therapy
toxin
therapy
Prior art date
Application number
BRPI0417493-3A
Other languages
English (en)
Inventor
Eric R First
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0417493A publication Critical patent/BRPI0417493A/pt
Publication of BRPI0417493B1 publication Critical patent/BRPI0417493B1/pt
Publication of BRPI0417493B8 publication Critical patent/BRPI0417493B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"TERAPIA COM TOXINA BOTULìNICA PARA DISTúBIOS DA PELE". A presente invenção refere-se a métodos para tratamento de distúrbios da pele po administração local de uma toxina clostridial, tal como uma toxina botulínica, a um paciente com um distúrbio de pele, tal como verruga, calosidade ou joanete.
BRPI0417493A 2003-12-09 2004-12-08 uso de uma toxina botulínica para tratamento de distúrbios da pele BRPI0417493B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/731,973 US8048423B2 (en) 2003-12-09 2003-12-09 Botulinum toxin therapy for skin disorders
PCT/US2004/041327 WO2005056050A1 (en) 2003-12-09 2004-12-08 Botulinum toxin therapy for skin disorders

Publications (3)

Publication Number Publication Date
BRPI0417493A true BRPI0417493A (pt) 2007-05-29
BRPI0417493B1 BRPI0417493B1 (pt) 2018-11-13
BRPI0417493B8 BRPI0417493B8 (pt) 2021-05-25

Family

ID=34634457

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417493A BRPI0417493B8 (pt) 2003-12-09 2004-12-08 uso de uma toxina botulínica para tratamento de distúrbios da pele

Country Status (10)

Country Link
US (1) US8048423B2 (pt)
EP (2) EP1820510B1 (pt)
JP (1) JP4937758B2 (pt)
AT (2) ATE446769T1 (pt)
AU (1) AU2004296870B2 (pt)
BR (1) BRPI0417493B8 (pt)
CA (1) CA2549550C (pt)
DE (2) DE602004023886D1 (pt)
ES (2) ES2335310T3 (pt)
WO (1) WO2005056050A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871224B2 (en) * 2003-12-09 2014-10-28 Allergan, Inc. Botulinum toxin therapy for skin disorders
US20080008777A1 (en) * 2004-02-12 2008-01-10 Philip Radovic Methods of treating a bunion
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US8497081B2 (en) 2004-02-24 2013-07-30 Allergan, Inc. Botulinum toxin screening assays
AU2005216547B2 (en) * 2004-02-24 2009-03-12 Allergan, Inc. Botulinum toxin screening assays
US20050191321A1 (en) * 2004-02-26 2005-09-01 Allergan, Inc. Methods for treating headache
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
US7922983B2 (en) * 2005-07-28 2011-04-12 Kimberly-Clark Worldwide, Inc. Sterilization wrap with additional strength sheet
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US8343929B2 (en) * 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
CA2875562A1 (en) * 2004-09-23 2006-03-30 Toxcure, Inc. Treating neoplasms with neurotoxin
MX2007003407A (es) * 2004-09-27 2007-05-23 Merz Pharma Gmbh & Co Kgaa Neurotixinas clostridiales.
US7655244B2 (en) 2005-02-01 2010-02-02 Allergan, Inc. Targeted delivery of botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions
US7749515B2 (en) * 2005-02-01 2010-07-06 Allergan, Inc. Targeted delivery of botulinum toxin to the sphenopalatine ganglion
US7419675B2 (en) * 2005-05-26 2008-09-02 Allergan, Inc. Method for treating peritoneal adhesions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
US7824694B2 (en) * 2006-01-12 2010-11-02 Allergan, Inc. Methods for enhancing therapeutic effects of a neurotoxin
CN101074935B (zh) * 2006-05-19 2011-03-23 清华大学 探测器阵列及设备
US8870876B2 (en) 2009-02-13 2014-10-28 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
US8696719B2 (en) 2010-06-03 2014-04-15 Tarsus Medical Inc. Methods and devices for treating hallux valgus
ES3036435T3 (en) * 2011-01-07 2025-09-18 Revance Therapeutics Inc Kits for topical application, removal, and inactivation of therapeutic or cosmetic botulinum toxin compositions
ES2424294B1 (es) 2012-03-22 2014-07-21 Lipotec, S.A. Exopolisacárido para el tratamiento y/o cuidado de la piel, mucosas, cabello y/o uñas
ES2660901T3 (es) 2012-04-13 2018-03-26 Lubrizol Advanced Materials, Inc. Compuestos que inhiben la exocitosis neuronal (II)
EP2649983A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (II)
EP2649985A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis (III)
EP2649984A1 (en) 2012-04-13 2013-10-16 Lipotec, S.A. Compounds which inhibit neuronal exocytosis
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2976060B1 (en) 2013-03-22 2016-10-26 Lipotec, S.A. Exopolysaccharide for the treatment and/or care of the skin, mucous membranes and/or nails
JP2020510100A (ja) 2017-03-13 2020-04-02 フィリップ アンドリュー ラドヴィッチ 足の第１中足趾節関節の異常の治療に使用するための神経筋毒素
RU2019143639A (ru) * 2017-05-31 2021-06-30 Аллерган, Инк. Ботулинический нейротоксин для лечения расстройств, связанных с гиперактивностью меланоцитов и/или избытком меланина

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
ATE215832T1 (de) 1994-05-09 2002-04-15 William J Binder Botulinumtoxin zur reduktion von migraine - kopfschmerzen
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
ATE216589T1 (de) * 1996-11-27 2002-05-15 William J Binder Neurotoxine zur behandlung von hauterkrankungen bei säugetieren
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
CA2347828A1 (en) 1998-10-27 2000-05-04 Mayo Foundation For Medical Education And Research Methods for enhancing wound healing
US6477410B1 (en) * 2000-05-31 2002-11-05 Biophoretic Therapeutic Systems, Llc Electrokinetic delivery of medicaments
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US7838007B2 (en) * 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating mammary gland disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
JP4138651B2 (ja) 2001-07-27 2008-08-27 ボード オブ スーパーバイザーズ オブ ルイジアナ ステイト ユニバーシティ アンド アグリカルチュラル アンド メカニカル カレッジ にきび治療または防止のためのボツリヌス毒素
DE10146647A1 (de) * 2001-09-21 2003-04-24 Marc Heckmann Arzneimittel zur Prophylaxe und Therapie von Bromhidrosis
US6945952B2 (en) * 2002-06-25 2005-09-20 Theraject, Inc. Solid solution perforator for drug delivery and other applications
KR100993477B1 (ko) * 2002-06-25 2010-11-11 권성윤 약물 송달 및 다른 용도를 위한 신속 용해형마이크로-퍼포레이터
US6776991B2 (en) * 2002-06-26 2004-08-17 Allergan, Inc. Methods for treating priapism
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
WO2004076634A2 (en) * 2003-02-24 2004-09-10 Ira Sanders Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease
US7335367B2 (en) * 2003-03-06 2008-02-26 Botulinum Toxin Research Associates, Inc. Treatment of chronic chalazion and hordeolum with botulinum toxin

Also Published As

Publication number Publication date
BRPI0417493B1 (pt) 2018-11-13
EP1820510A1 (en) 2007-08-22
EP1691830A1 (en) 2006-08-23
DE602004008329D1 (de) 2007-09-27
ES2289591T3 (es) 2008-02-01
EP1820510B1 (en) 2009-10-28
US20050123567A1 (en) 2005-06-09
WO2005056050A1 (en) 2005-06-23
DE602004008329T2 (de) 2008-05-08
ES2335310T3 (es) 2010-03-24
US8048423B2 (en) 2011-11-01
BRPI0417493B8 (pt) 2021-05-25
DE602004023886D1 (de) 2009-12-10
AU2004296870A1 (en) 2005-06-23
CA2549550A1 (en) 2005-06-23
JP2007513964A (ja) 2007-05-31
ATE369874T1 (de) 2007-09-15
AU2004296870B2 (en) 2010-05-20
CA2549550C (en) 2012-07-17
JP4937758B2 (ja) 2012-05-23
EP1691830B1 (en) 2007-08-15
ATE446769T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
BRPI0417493B8 (pt) uso de uma toxina botulínica para tratamento de distúrbios da pele
BR0111698A (pt) Método para o tratamento de um distúrbio de movimento
NZ603717A (en) Suture line administration technique using botulinum toxins
BR0309888A (pt) Tratamento intracraniano de distúrbios neuropsiquiátricos por neurotoxinas clostridiais tal como a toxina da botulina
MX2022015613A (es) Composiciones de benzofurano beneficiosas para trastornos mentales o mejoramiento mental.
BR0110030A (pt) Método para tratamento de dor através da administração periférica de uma neurotoxina
BR0318269A (pt) composições, alvos, métodos e dispositivos para a terapia de distúrbios oculares e perioculares
MXPA03002576A (es) Metodos para tratar lesiones musculares.
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BR0014710A (pt) Métodos para o tratamento de dor
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
BRPI0502346A (pt) processo de tratamento cosmético para prevenir e/ou tratar as peles sensìveis e/ou secas, utilização de uma quantidade eficaz de pelo menos um microorganismo notadamente probiótico e/ou uma de suas frações e/ou um de seus metabólitos e composição cosméticas e/ou dermatológica
BRPI0612119A2 (pt) tratamento de distúrbio auto-imunes com uma neuroxotina
BR0310099A (pt) método para tratar dislipidemia ou uma doença associada com a dislipidemia
BR112014009851A2 (pt) moduladores de receptor de nmda e usos dos mesmos
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2013013809A (es) Dispositivos expandibles con revestimiento de una composicion de paclitaxel.
EP3818991A3 (en) Compositions and methods for treating diseases
SG10201805552PA (en) Sodium channel modulators for the treatment of pain and diabetes
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
WO2019166412A9 (en) Modulation of pla2-g1b in therapy
BR112014001170A2 (pt) cateter, especialmente um cateter permanente, para tratamento de problemas funcionais e/ou doenças da bexiga e/ou próstata
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
BRPI0415215A (pt) aplicação de um polifenol para o tratamento de uma lesão cancerosa ou pré-cancerosa da pele
MX394918B (es) Neurotoxinas botulinas para uso en terapia

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09T Decision of refusal: decision cancelled [chapter 9.2.1 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 9.2 NA RPI NO 2463 DE 20/03/2018 POR TER SIDO INDEVIDA.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/11/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.